Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1864663 (HCC)
 2,985 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Dairy cows were injected with 1 alpha-hydroxycholecalciferol (1 alpha-HCC) and, or, cloprostenol at 275 days of gestation. Blood samples were taken daily from 270 days of gestation until seven days after parturition and analysed for calcium, inorganic phosphate, magnesium and hydroxyproline. In all treated and control cows concentrations of calcium, inorganic phosphate and magnesium decreased around the time of parturition. Concentrations of hydroxyproline increased from the second to the fourth day after parturition. This increase was slightly smaller in cows injected with cloprostenol but was unaffected by 1 alpha-HCC. There was a greater indicence of retained placenta and endometritis in cows receiving cloprostenol. The injection of cloprostenol with 1 alpha-HCC at 275 days of gestation did not prevent milk fever.
Vet Rec 1981 Oct 17
PMID:Study of combined injections of 1 alpha-hydroxy-cholecaldiferol and cloprostenol in the prevention of parturient paresis. 703 60

The efficacy of 1 alpha-hydroxycholecalciferol (1 alpha-HCC) for the prevention of milk fever has been tested in a controlled field trial using a total of 601 cows on 18 farms with a history of a high incidence of milk fever. The trial protocol proposed two doses of 1 alpha-HCC with the first injection seven days before the predicted calving date and a second injection five to seven days later if the cow had not calved. Of 301 cows receiving either one or two injections of 1 alpha-HCC, 70 had milk fever, and of 300 cows that received a placebo, 102 had milk fever. The difference in incidence between the two groups was statistically significant (P = 0.005) and indicated an overall efficacy of 32 per cent for treatment with 1 alpha-HCC. An improved efficacy was demonstrated in 67 cows that received two injections of 1 alpha-HCC with the second injection administered either on the day of calving or one day previously (60 per cent efficacy). For 42 cows that received a single injection of 1 alpha-HCC between two and five days before calving an efficacy of 79 per cent was achieved.
Vet Rec 1981 Sep 26
PMID:Field trial to determine the efficacy of two doses of 1 alpha-hydroxycholecalciferol in the prevention of milk fever. 703 76

Varying doses of 1 alpha-hydroxycholecalciferol (1 alpha-HCC) (50, 150, 250 and 350 micrograms) in propylene glycol were injected intramuscularly into 30 dry adult Israeli Friesian cows. Fourteen of these animals received a second dose; four were given 250 or 350 micrograms 48 hours after the first dose and 10 were given 350 micrograms 72 hours after the first dose. Plasma calcium rose after 24 hours at all dose levels except 50 micrograms. A dose-dependent peak in plasma calcium was reached after three to four days, followed by a return to baseline five days (150 micrograms) and eight days (250 and 350 micrograms) post injection respectively. Repeating the injection 48 or 72 hours later increased the time span by three and four days respectively. The effect of plasma inorganic phosphate was double that on plasma calcium. Plasma magnesium declined slightly three days post injection. High calcium feeding in conjunction with one or two injections of 350 micrograms 1 alpha-HCC did not modify the response of plasma calcium. An injection of 350 micrograms of 1 alpha-HCC was given once to 40 parturient paresis-prone cows of the same breed and twice at 72-hour intervals to 37 such cows. Six of the animals received 5 mg of flumethasone together with the second injection and 13 received it 48 hours later. This was to induce parturition, which occurred within 24 to 48 hours. None of the cows injected earlier than 24 hours prepartum developed parturient paresis in comparison with 22 out of 60 control animals which did. The results suggest that 1 alpha-HCC is useful in the prevention of bovine parturient paresis.
Vet Rec 1980 Jun 21
PMID:Observations of the use of 1 alpha hydroxycholecalciferol in the prevention of bovine parturient paresis. 743 21

KiSS-1 has been identified as a putative metastasis-suppressor gene in human melanomas and breast cancer cell lines. Although loss of KiSS-1 expression has been associated with progression and poor prognosis of various cancers, the exact role of KiSS-1 expression in HCC is not well-defined. Our study investigated KiSS-1 expression levels in HCC and its role in invasion and metastasis of human HCC. The expression levels of KiSS-1 and MMP-9 protein were determined by tissue microarray (TMA) serial sections, immunohistochemistry and semi-quantitative image analysis. All clinical and histological data obtained were subjected to statistical analysis. The expression of KiSS-1 protein in HCC and intrahepatic metastasis lesions was significantly lower (P < 0.01) when compared with non-tumor liver tissue and normal liver tissue. Multivariate analysis revealed a significant inverse correlation between KiSS-1 expression and o1 TNM stage, (F = 7.113, P < 0.01) and o2 intrahepatic metastasis (t = 2.898, P < 0.01). Loss of KiSS-1 in intrahepatic metastasis versus primary carcinomas was statistically significant (P<0.01). We also found a negative correlation between KiSS-1 and MMP-9 expression in HCC (r = -0.506, P < 0.01). We conclude that loss of KiSS-1 during HCC metastasis, along with a concomitant upregulation of MMP-9 suggests a possible mechanism for cell motility and invasion during HCC metastasis, with KiSS-1 emerging as a possible therapeutic target during HCC metastasis.
Anat Rec (Hoboken) 2009 Aug
PMID:Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. 1964 16

Direct-acting antivirals (DAAs) revolutionised the treatment of chronic HCV-related disease achieving high rates of sustained virological response (SVR), also in more advanced patients, with a good safety profile and a proven positive effect on the reduction of risk of HCC occurrence. Nevertheless, patients with an history of successfully treated early HCC were initially excluded from pivotal trials. Although some initial retrospective studies, affected by several methodological issues, raised concerns regarding a possible harmful effect on the risk of HCC recurrence after antiviral therapy, more rec
 ...
PMID:Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 3066 91